Abstract Details

Title Blood-Brain Barrier Opening with Focused Ultrasound in Parkinson´s Disease Dementia: A Safety and Feasibility Study

Topic Movement Disorders

Presentation(s) P1 - Poster Session 1 (12:00 PM-1:00 PM)

Poster/Presentation
Number 3-001

Objective To evaluate safety and feasibility of MR guided focused ultrasound (MRgFUS)- blood brain barrier (BBB) opening in PDD and putative changes in cognition and PET.

Background

The prevalence of dementia in Parkinson´s disease (PD), reaches about 80% 20 years after diagnosis. In PD dementia (PDD), there is high combination of mixed Alzheimer´s and PD pathology and current treatments provided very modest benefit. BBB penetration limitations is a major restriction for many putative therapeutic agents. Low frequency/energy MRgFUS in combination with parenteral microbubbles administration leads to focal temporarily BBB opening, becoming a putative therapeutic tool for drug delivery.

Design/Methods

This is an open, proof-of-concept, safety and feasibility pilot study of focal BBB opening in PDD. Five patients underwent MRgFUS procedure to open BBB at the right parietooccipitotemporal cortex twice, separated by at least two weeks. Immediately and 1 and 7 days after the procedure, brain MR with gadolinium was taken to detect enhancement indicating BBB opening. Amyloid and fluordeoxyglucose PET were performed before treatment and 3 weeks after the second BBB opening session.

Results Five patients were included in the study. BBB was opened satisfactorily after the treatmentand was closed in all cases by day 7th. There were no major side effects and mild improvement in several cognitive domains was observed. Discrete round hypointensities on MRI SWAN sequences (sonicated region) were seen immediately after treatment. These disappeared progressively except for one patient who still showed some minor abnormalities after 2 months. There were no major changes from pre to post treatment in PET studies.

Conclusions This study suggests that MRgFUS-BBB opening in PDD is safe, reversible and can be done repeatedly. Therapeutic trials combining parenteral drug delivery and BBB opening can be envisaged to treat neurodegenerative dementia.

Authors/Disclosures
Carmen Gasca-Salas, MD PRESENTER	Dr. Gasca-Salas has received personal compensation in the range of $500-$4,999 for serving as a Speaker (lecturing) with Esteve and Exeltis.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Jose A. Obeso, MD (CINAC)	No disclosure on file